SI
MBX

Symmetry Investments’s MBX Biosciences MBX Stock Holding History

Symmetry Investments’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$175K – 214
2025
Q3 		$175K Buy
+10,000
New +$134K 0.01% 137

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Symmetry Investments's MBX Position: Q4 2025 in Review

Symmetry Investments sold out of MBX Biosciences (MBX) in Q4 2025, closing a stake of 10,000 shares — an estimated $175K sold.

Symmetry Investments first reported a position in MBX in Q3 2025 and held it in 1 quarter. The position peaked at $175K in Q3 2025. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

  • Symmetry Investments reported no remaining MBX Biosciences position as of Q4 2025 after selling out during the quarter.
  • Symmetry Investments sold 10,000 MBX Biosciences shares in Q4 2025, an estimated $175K.
  • Symmetry Investments first reported a position in MBX Biosciences in Q3 2025 and held it in 1 quarter.
  • Symmetry Investments's MBX Biosciences position peaked at $175K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on Symmetry Investments's 13F filing for Q4 2025, filed 17 Feb 2026.